Citations

Clear

10 citation(s) found for "Gil, Beatriz Fernandez".

TMOD-45. Immune Competent Glioblastoma Models for Therapeutic Translation
Michaelides, Loizos , Julian, M.W., Gil, Beatriz Fernandez, Jones, Vanessa K. , Brooks, Mieu, Pluhar, L., Julian, Maddy, Schiapparelli, Paula , Arnold, Susan , Tzeng, Stephany Y. , Green, Jordan J. , ReFaey, Karim

Mayo Clinic

Neuro-Oncology | November 11, 2025 | Volume: 27 | Issue: Supplement_5 | Pages: v484-v484

10.1093/neuonc/noaf201.1918 Get It

Abstract Spontaneously arising canine high-grade gliomas (cHGG) offer a clinically relevant model for human glioblastoma, sharing conserved histopathological, genetic, and immunological traits. We established two cHGG cell lines and two canine adipose-derived mesenchymal stem cell (cAMSC) lines, and immune-competent 3D cHGG organoid models. Immunoblotting of cHGG cell lines showed that these models exhibit hallmark GBM features including SOX2, Nestin, GFAP, and activation of PI3K/AKT and p53 pathways. Given the established cytotoxic and differentiation-inducing effects of BMP4 in human GBM cell lines, we evaluated whether our canine glioma models recapitulate these responses to assess their translational relevance. BMP4 treatment of cHGG cells induced significant cytotoxicity and reduced migration, accompanied by downregulation of SOX2 and Nestin, upregulation of GFAP, and suppression of CDK6 and phospho-AKT—hallmarks of reduced stemness and astrocytic differentiation. In human-derived GBM cells, BMP4 enhanced radiosensitivity, likely via differentiation and depletion of therapy-resistant stem-like populations. Our cHGG models mirrored these molecular responses, suggesting a conserved BMP4 signaling axis in canine glioma. Quantitative phase imaging showed that BMP4 treatment was non-toxic to cAMSCs and did not impair their migration, supporting the feasibility of engineering cAMSC-BMP4 for therapeutic delivery. Observed molecular traits in canine and human gliomas—including mutually exclusive mutations in PDGFRA and PIK3CA, and shared expression of TP53, PTEN, p21, Rb1, mTOR, and MAPK—underscore the translational relevance of the cHGG model. High-content imaging further confirmed expression of p-AKT, p53, MDM2, and CD44 in cHGG lines, reinforcing activation of conserved gliomagenic pathways. To complement these findings, we developed a cHGG 3D organoids from freshly resected tumors, that recapitulate tumor heterogeneity with co-localized GFAP+/Nestin+ glioma cells, CD3+ infiltrating T cells, macrophages and cleaved caspase-3+ apoptotic cells, indicating active immune surveillance and ongoing programmed cell death. Our results support canine GBM model as a platform to assess glioma biology, cell therapy, and modeling immune engagement in a species-relevant, physiologically intact environment for streamlined translation of therapeutics to human clinical trials.
TMET-60. Dual Pathway Inhibition Triggers Glioblastoma Metabolic Collapse
Michaelides, Loizos , Gil, Beatriz Fernandez, Llano, Juan Pablo Navarro Garcia de, Weil, Raegan, Morales‐Gallel, Raquel , Dammen‐Brower, Kris , Aafreen, Safiya , Ulloa-Navas, María José , Yarema, Kevin J. , Weil, Raegan, García‐Verdugo, José Manuel , ReFaey, Karim

Mayo Clinic

Neuro-Oncology | November 11, 2025 | Volume: 27 | Issue: Supplement_5 | Pages: v442-v442

10.1093/neuonc/noaf201.1751 Get It

Abstract Glioblastoma is an aggressive brain cancer with poor prognosis. Recent evidence implicates metabolic reprogramming, including the hexosamine biosynthetic pathway (HBP) and pentose phosphate pathway (PPP), as critical for tumor survival, therapy resistance, and progression. HBP inhibition with a proprietary small molecule (G2Bz) reduced stemness and migration and increased apoptosis of GBM in vitro. HBP inhibition was concomitant with an accumulation of metabolites in the Pentose Phosphate Pathway (PPP). Therefore, we further inhibited HBP with G2Bz and/or PPP with 6-aminonicotinamide (6-AN) in primary patient-derived GBM lines and evaluated additive or synergistic effects. Ultrastructural and functional changes were examined by electron microscopy (EM), high content imaging of endoplasmic reticulum (ER) and lipid droplets (LD), extracellular-flux analysis, and lipid profiling. Synergism was validated in an orthotopic model receiving lipoparticle-encapsulated G2Bz via intranasal delivery and/or intraperitoneal 6-AN; tumor burden was monitored via bioluminescence. Dual inhibition of HBP/PPP revealed additive or synergistic anti-proliferative effect. EM displayed severe ultrastructural cell damage with mitochondrial disorganization, ER dilation, and cytoskeletal remodeling. These changes coincided with increased ROS generation and reduced spare respiratory capacity suggesting higher sensitivity and lower ability to fight stress. Reduced ER–mitochondria contacts accompanied by increased expression of BiP and ER expansion suggest an unfolded protein response. Loss of LDs were associated with downregulation of lipid biosynthesis regulator SREBF1 and an increase in free fatty acids with a rise in lipid peroxidation. Reduced mitochondria–LD contacts correlate with lower endogenous fatty acid oxidation and a shift to exogenous fatty acid utilization. Dual inhibition in-vivo, suppressed tumor growth compared to control. These findings support that dual inhibition of HBP/PPP synergistically disrupts tumor metabolism, promoting organelle disorganization and lipid remodeling and highlight metabolic co-targeting as a strategy to impair GBM metabolism.
Surface-engineered dual drug-loaded tumor-targeted liposomal nanoparticles to overcome the therapeutic resistance in glioblastoma multiforme
Angom, Ramcharan Singh , Suárez-Meade, Paola , Gil, Beatriz I Fernandez, Wei, Raegan, Datta, Shamit Kumar, Wang, Enfeng , Quiñones‐Hinojosa, Alfredo , Singh Angom, Ramcharan , Nakka, Naga Malleswara Rao , Madamsetty, Vijay Sagar , Saurez Meade, Paola, Weil, Raegan, Dutta, Shamit, Quinones-Hinojosa, Alfredo , Mukhopadhyay, Debabrata , Rachamala, Hari Krishnareddy, Fernández-Gil, Beatriz I. , Kulkarni, Tanmay , Weil, Raegan M., Dutta, Shamit K., Bhattacharya, S., Pal, Krishnendu , Mukhopadhyay, Debabrata

Mayo Clinic

No container title available | October 31, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-6080830/v1 | PMID 41282050 Get It

Abstract Background Glioblastoma (GBM) is the most common high-grade primary malignant brain tumor, characterized by a notably poor prognosis. Current treatments for GBM have shown limited effectiveness in improving patient survival, highlighting the urgent need for novel therapeutic strategies. Combination therapy offers significant potential in overcoming resistance by targeting multiple signaling pathways; however, it often comes with increased toxicity compared to monotherapy. Co-encapsulating multiple therapeutic agents into a tumor-targeted drug delivery platform holds promise for overcoming these limitations and improving treatment outcomes. Methods We developed a tumor-targeted liposomal nanoformulation (TTL) using phospholipids, cholesterol, DSPE-(PEG)2000-OMe, and a proprietary tumor-targeting peptide (TTP). The TTL was loaded with everolimus (TTL-E), vinorelbine (TTL-V), rapamycin (TTL-R), a combination (TTL-EV), or (TTL-RV). These formulations were tested in vivo on orthotopic GBM mice, combined with temozolomide and radiation. RNA sequencing was performed to identify molecular and transcriptome changes post-treatment. Results TTL demonstrated tumor-specific uptake, effectively delivering drugs to GBM tumors. TTL-EV and TTL-RV outperformed single-drug formulations. Radiation combined with TTL-EV/RV improved tumor growth inhibition and survival, while temozolomide provided minimal benefit. Transcriptome analysis revealed differentially expressed genes (DEGs) linked to DNA damage repair, cell cycle, metabolism, and extracellular matrix pathways. Conclusion TTL crossed the blood-brain barrier, targeting tumors effectively. Radiation plus TTL-EV/RV enhanced tumor suppression and survival in GBM models. Gene expression analysis identified DEGs related to DNA damage and cell death. Mechanistic studies suggest TTL-EV plus radiation inhibits mTOR/MAPK pathways and sensitizes tumors to radiation. These findings offer a potential approach for improving GBM treatment.
Anticancer Properties of Hexosamine Analogs Designed to Attenuate Metabolic Flux through the Hexosamine Biosynthetic Pathway
Saeui, Christopher T. , Shah, Sagar , Fernández-Gil, Beatriz I. , Zhang, Cissy, Agatemor, Christian , Dammen‐Brower, Kris , Buettner, Matthew J., Gowda, P. , Khare, Pratik, Otamendi-Lopez, Andrea, Yang, Shuang , Quiñones‐Hinojosa, Alfredo , Yarema, Kevin J. , Gowda, Prateek , Yang, Shuang , Zhang, Hui , Yarema, Kevin J , Mathew, Mohit Philip , Le, Anne

Mayo Clinic

ACS Chemical Biology | January 10, 2023 | Volume: 18 | Issue: 1 | Pages: 151-165

10.1021/acschembio.2c00784 | PMID 36626752 Get It

Melatonin Treatment Triggers Metabolic and Intracellular pH Imbalance in Glioblastoma
Fernández-Gil, Beatriz I. , Otamendi-Lopez, Andrea, Bechtle, Alexandra , Vazquez-Ramos, Carla , Qosja, Neda, Suárez-Meade, Paola , Jentoft, Mark E. , Guerrero‐Cazares, Hugo , Escames, Germaine , Quiñones‐Hinojosa, Alfredo , Vazquez-Ramos, Carla A, Guerrero-Cazares, Hugo , Escames, Germaine , Schiapparelli, Paula , Sarabia-Estrada, Rachel

Mayo Clinic

Cells | November 3, 2022 | Volume: 11 | Issue: 21 | Pages: 3467

10.3390/cells11213467 | PMID 36359862 Get It

Metabolic rewiring in glioblastoma (GBM) is linked to intra- and extracellular pH regulation. In this study, we sought to characterize the role of melatonin on intracellular pH modulation and metabolic consequences to identify the mechanisms of action underlying melatonin oncostatic effects on GBM tumor initiating cells. GBM tumor initiating cells were treated at different times with melatonin (1.5 and 3.0 mM). We analyzed melatonin’s functional effects on GBM proliferation, cell cycle, viability, stemness, and chemo-radiosensitivity. We then assessed the effects of melatonin on GBM metabolism by analyzing the mitochondrial and glycolytic parameters. We also measured the intracellular and extracellular pH. Finally, we tested the effects of melatonin on a mouse subcutaneous xenograft model. We found that melatonin downregulated LDHA and MCT4, decreasing lactate production and inducing a decrease in intracellular pH that was associated with an increase in ROS and ATP depletion. These changes blocked cell cycle progression and induced cellular death and we observed similar results in vivo. Melatonin’s cytotoxic effects on GBM were due, at least in part, to intracellular pH modulation, which has emerged as a newly identified mechanism, providing new insights into the oncostatic effect of melatonin on GBM.
Melatonin Targets Metabolism in Head and Neck Cancer Cells by Regulating Mitochondrial Structure and Function
Guerra‐Librero, Ana , Fernández-Gil, Beatriz I. , Florido, Javier , Martínez-Ruiz, Laura , Rodríguez-Santana, César , Shen, Yingqiang , García‐Verdugo, José Manuel , López‐Rodríguez, Alba , Rusanova, Iryna , Quiñones‐Hinojosa, Alfredo , Acuña-Castroviejo, Darı́o , Marruecos, J., Haro, Tomás de , Escames, Germaine , García-Verdugo, José M , Escames, Germaine

Mayo Clinic

Antioxidants | April 14, 2021 | Volume: 10 | Issue: 4 | Pages: 603

10.3390/antiox10040603 | PMID 33919790 Get It

Metabolic reprogramming, which is characteristic of cancer cells that rapidly adapt to the hypoxic microenvironment and is crucial for tumor growth and metastasis, is recognized as one of the major mechanisms underlying therapeutic resistance. Mitochondria, which are directly involved in metabolic reprogramming, are used to design novel mitochondria-targeted anticancer agents. Despite being targeted by melatonin, the functional role of mitochondria in melatonin’s oncostatic activity remains unclear. In this study, we aim to investigate the role of melatonin in mitochondrial metabolism and its functional consequences in head and neck cancer. We analyzed the effects of melatonin on head and neck squamous cell carcinoma (HNSCC) cell lines (Cal-27 and SCC-9), which were treated with 100, 500, and 1500 µM of melatonin for 1, 3, and 5 days, and found a connection between a change of metabolism following melatonin treatment and its effects on mitochondria. Our results demonstrate that melatonin induces a shift to an aerobic mitochondrial metabolism that is associated with changes in mitochondrial morphology, function, fusion, and fission in HNSCC. We found that melatonin increases oxidative phosphorylation (OXPHOS) and inhibits glycolysis in HNSCC, resulting in increased ROS production, apoptosis, and mitophagy, and decreased cell proliferation. Our findings highlight new molecular pathways involved in melatonin’s oncostatic activity, suggesting that it could act as an adjuvant agent in a potential therapy for cancer patients. We also found that high doses of melatonin, such as those used in this study for its cytotoxic impact on HNSCC cells, might lead to additional effects through melatonin receptors.
DDRE-33. MELATONIN AS A MASTER METABOLIC SWITCH FOR GLIOBLASTOMA
Vazquez-Ramos, Carla , Bechtle, Alexandra , Suárez-Meade, Paola , Qosja, Neda, Quiñones‐Hinojosa, Alfredo , Fernández-Gil, Beatriz I. , Schiapparelli, Paula , Sarabia-Estrada, Rachel , Escames, Germaine

Mayo Clinic

Neuro-Oncology Advances | March 25, 2021 | Volume: 3 | Issue: Supplement_1 | Pages: i13-i14

10.1093/noajnl/vdab024.055 Get It

Abstract Glioblastoma (GBM) is the most common form of malignant primary brain cancer in adults with a median survival of only 15 months. Therefore, new therapies to suppress malignant brain cancer are needed. Brain Tumor Initiating Cells (BTICs) are a GBM subpopulation of cells with a highly glycolytic profile that are thought to be responsible of the resistance of GBM to treatments. Metabolic reprogramming allows tumor cells to survive in unsupportive microenvironments. Manipulating tumor metabolism to counteract GBM resistance arises as a powerful approach with minimum effects in normal counterparts. At pharmacological concentrations, melatonin displays oncostatic properties. This is thought to be due to an increase in mitochondrial oxidative phosphorylation through the effects of melatonin in mitochondria, key organelle in metabolic homeostasis. We hypothesize that melatonin could alter BTIC metabolism, by inducing an anti-Warburg effect and as consequence, melatonin will decrease the viability of GBM cells and tumor growth. We found that treatment of GBM cell lines with 3mM melatonin significantly altered tumor cell metabolism. We observed that melatonin downregulated the lactate symporter MCT4 (p<0.002), inducing a significant intracellular accumulation of lactate (p<0.002) while decreasing it in the extracellular media (p<0.001). This was followed by a decrease in the internal pH (p<0.002). These effects were compensated by an increase in the oxygen consumption rate (OCR) followed by decay that leaded to an increase in ROS production (p<0.001). All these changes result in a depletion of cellular ATP (p<0.001) and eventually drove to a decrease in the proliferation (p<0.001) and cell death (p<0.001). When applied in vivo we observed a significant reduction in the tumor growth (p<0.001), volume (p<0.002) and weight (p<0.002), as well as a drop in the proliferation marker ki67 (p<0.001) and a fibrosis increase in treated tumors. These results position melatonin as a strong therapeutic candidate for GBM therapy.
BSCI-27. MELATONIN REDUCES MALIGNANCY OF BREAST CANCER BRAIN METASTATIC CELLS
Gil, Beatriz Fernandez, Rodríguez, Katherine , Ramos, Carla Vazquez, Quiñones‐Hinojosa, Alfredo , Schiapparelli, Paula , Escames, Germaine , Sarabia-Estrada, Rachel

Mayo Clinic

Neuro-Oncology Advances | August 12, 2019 | Volume: 1 | Issue: Supplement_1 | Pages: i6-i6

10.1093/noajnl/vdz014.023 Get It

Abstract Around fifteen to thirty percent of stage IV breast cancer metastasizes to the brain, severely decreasing the quality of life of these patients by causing neurological decline and eventually death. In metastatic cancers there is a small subset of cells in the primary tumor bulk called Metastatic Tumor Initiating Cells (MTICs) which are able to escape and produce a niche establishment at distal sites where they can quickly become resistant to surgery and radiation. Melatonin has shown an inhibitory role in the viability and invasiveness of breast cancer and in modulating the expression of proteins related to Breast Cancer Stem Cells (BCSCs). These findings suggest its potential anti-metastatic role in different breast cancer cell lines. In this study we aimed to evaluate the effects of melatonin treatment in vitro for breast cancer brain metastasis. The cell line MDA-BT was originally obtained from MDA-MB-231, passed through the rat’s heart and then isolated once engrafted as a tumor in the brain. After a dose response assay, cells were treated with melatonin at doses of 1500 and 3000 µM for 48hrs. Clonogenic assay, MTT, as well as a stem cell signature through RT-qPCR, including CD44, CD24 and ALDH1 markers, were performed to evaluate the malignancy of the MTICs. The results showed that melatonin at high doses impacts morphology, declines viability, reduces colony formation ability, and decreases stemness in MDA-BT cells. Therefore, our findings highlight melatonin as a relevant therapeutic candidate to target breast cancer brain metastases.
Melatonin Enhances Cisplatin and Radiation Cytotoxicity in Head and Neck Squamous Cell Carcinoma by Stimulating Mitochondrial ROS Generation, Apoptosis, and Autophagy
Fernández-Gil, Beatriz I. , Guerra‐Librero, Ana , Shen, Yingqiang , Florido, Javier , Martínez-Ruiz, Laura , García‐López, Sergio, Adan, Christian, Rodríguez-Santana, César , Acuña-Castroviejo, Darı́o , Quiñones‐Hinojosa, Alfredo , Moneim, Ahmed E. Abdel , Ferrer, José M. Rodríguez, Escames, Germaine , Abdel Moneim, Ahmed E , Escames, Germaine , García-López, Sergio, Fernández‐Martínez, José , López, Luis Carlos

Mayo Clinic

Oxidative Medicine and Cellular Longevity | February 28, 2019 | Volume: 2019 | Issue: No issue available | Pages: 1-12

10.1155/2019/7187128 | PMID 30944696 Get It

Head and neck cancer is the sixth leading cancer by incidence worldwide. Unfortunately, drug resistance and relapse are the principal limitations of clinical oncology for many patients, and the failure of conventional treatments is an extremely demoralizing experience. It is therefore crucial to find new therapeutic targets and drugs to enhance the cytotoxic effects of conventional treatments without potentiating or offsetting the adverse effects. Melatonin has oncostatic effects, although the mechanisms involved and doses required remain unclear. The purpose of this study is to determine the precise underlying mitochondrial mechanisms of melatonin, which increase the cytotoxicity of oncological treatments, and also to propose new melatonin treatments in order to alleviate and reverse radio- and chemoresistant processes. We analyzed the effects of melatonin on head and neck squamous cell carcinoma (HNSCC) cell lines (Cal-27 and SCC-9), which were treated with 0.1, 0.5, 1, and 1.5 mM melatonin combined with 8 Gy irradiation or 10 μM cisplatin. Clonogenic and MTT assays, as well as autophagy and apoptosis, involving flow cytometry and western blot, were performed in order to determine the cytotoxic effects of the treatments. Mitochondrial function was evaluated by measuring mitochondrial respiration, mtDNA content (RT-PCR), and mitochondrial mass (NAO). ROS production, antioxidant enzyme activity, and GSH/GSSG levels were analyzed using a fluorometric method. We show that high concentrations of melatonin potentiate the cytotoxic effects of radiotherapy and CDDP in HNSCC, which are associated with increased mitochondrial function in these cells. In HNSCC, melatonin induces intracellular ROS, whose accumulation plays an upstream role in mitochondria-mediated apoptosis and autophagy. Our findings indicate that melatonin, at high concentrations, combined with cisplatin and radiotherapy to improve its effectiveness, is a potential adjuvant agent.
CADD-28. MELATONIN: TARGETING THE CELL’S POWERHOUSE TO FIGHT GLIOBLASTOMA
Schiappareli, Paula, Vazquez-Ramos, Carla , Quiñones‐Hinojosa, Alfredo , Fernández-Gil, Beatriz I. , Sarabia-Estrada, Rachel , Escames, Germaine

Mayo Clinic

Neuro-Oncology | November 5, 2018 | Volume: 20 | Issue: suppl_6 | Pages: vi280-vi281

10.1093/neuonc/noy148.1169 Get It